Research notes

We update for 2Q production and trimmed NEWC price forecasts. We think dividend expectations should be moderated at the 1H Result March 19th. NHC’s defensive attributes – cash margins, balance sheet, steady dividends - appear to have supported a recent premium relative to more leveraged peers. Maintain Hold as NHC trades near to fair value. Our forecast 7-8% yield looks like sound compensation as investors await the next upswing.

GMG continued its upgrade trend, with FY24 EPS growth guidance increasing from +9% to +11%, implying what appears to be a conservative sequential decline of 23% (hoh). The 1H24 result beat VA consensus EPS expectations by 13%, with the standout being the development division, supported by a larger proportion of developments being undertaken on balance sheet (higher margin). The business continues to benefit from the structural demand drivers of the digital economy, namely increased investment in technology and tenant’s need to maximise productivity. This has seen data centre projects rise to 37% of WIP. At $28.5/sh, the stock is trading c.1 standard deviation expensive and at a 12 month forward PER of 27x. For a business growing mid to high double digits, the stock isn’t cheap. Offsetting this is the quality: a portfolio of global assets spanning the most attractive subsectors of the real estate market and a management team capable of delivering EPS growth. Weighing this up, we see GMG as a great business and an essential part of any real estate allocation but too expensive to be a buyer at these prices, despite the earnings upside.

QBE’s FY23 NPAT (A$1.36bn) was -2% below consensus (A$1.383bn), with FY24 guidance also slightly softer than expected. While headline numbers were marginally weaker than hoped, fundamentally we saw this as a good FY23 result delivering a 16% ROE, and with a very strong balance sheet (PCA capital ratio of 1.82x versus 1.6x-1.8x target). In our view, the QBE investment thesis still remains very much intact, with the company on track to deliver ~25% EPS growth in FY24, whilst trading on a sub 10x PE multiple. This is too cheap in our view. We lower our QBE FY24F/FY25F EPS by ~-2%-3% on slightly softer GWP and margin assumptions. Our PT rises slightly to A$17.96 (previously A$17.56) with our earnings changes offset by a valuation roll-forward.

1H24 delivered the strong EBIT growth required to contribute to management incentive targets in FY26. However, there were headwinds to EPS and cashflow tracking at the same pace. Our target price lifts 14 cps to $2.54, from forecast upgrades (+4 cps) and valuation roll-forward (+10 cps). HOLD retained. At current prices we estimate a 12 month TSR of -3% and a five year IRR of c.7% pa.

IAG’s 1H23 NPAT (A$407m) was down -13% on the pcp, and ~-7% below Visible Alpha consensus. While IAG’s headline result numbers were a bit softer than expected, full year guidance was re-affirmed, and IAG does enter 2H24 with its underlying insurance margin (UIM) seemingly already tracking around 15%. We downgrade IAG FY24F/FY25F EPS by -6%/-2% on slightly softer UIM forecasts and higher interest expense. Our PT is set at A$6.17 (previously A$6.32). We believe IAG is now generally tracking in the right direction operationally after a difficult few years, however, with <10% upside to our valuation we maintain our HOLD call.

ING reported the strongest 1H result in its listed life. However, it was the materially softer than expected volume growth in Australia which disappointed following weakness in the ‘out of home’ channels. Management’s outlook commentary was vague as usual and slightly cautious. However, its commentary around the 1H/2H skew is unchanged. Our EBITDA forecasts are therefore unchanged while NPAT falls slightly due to higher tax. Given expectations were high leading into this result following strong share price performance in recent months, the stock was sold off given there was no beat and outlook commentary was mixed. However, we think the stock has been severely oversold. Trading on an FY25F PE of 11.1x and an attractive dividend yield of 6.1% fully franked, we maintain an Add rating.

Despite revenue growth of 2.4% on pcp to ~A$512m, ASX’s 1H24 result was a miss versus market consensus at NPAT (~A$231m, -8% on pcp and ~6% under consensus) on higher total costs than expected (~A$221m, +27% on pcp). We alter our FY24F-FY26F EPS by ~-2-+2% on higher operating expenses near term with an improved margin profile (cost rationalisation) medium-term. Our price target increases to A$62.70 (from A$60.20). Trading on ~26.5x MorgE FY24F PE, slightly above its 10-year average, we still see the elevated expense profile as weighing on the stock near-term. Hold maintained.

Portfolio fundamentals remain solid and properties continue to re-weight towards higher growth Daily Needs assets vs Large Format Retail. One acquisition and four divestments to settle in 2H24. LFL income grew 4% which is in line with guidance and the active development pipeline remains on track to complete in 2H24 which will assist in valuation uplifts. Planning on new developments valued at +$530m is underway. NTA $1.44. FY24 guidance reaffirmed comprising FFO of 8.6c and DPS of 8.3c. We retain an Add rating with a price target of $1.37.

GQG reported a strong and in-line FY23 result: mgmt fees +16.8%; operating profit +15.7%; NPAT +18.7%. 2H23 earnings were up 19.7% half on half. Investment performance has been solid/strong across all strategies. This supports flows, which have commenced strongly (US$2.9bn CY to-date vs US$2.2bn pcp). Recent FUM growth provides near-term earnings growth visibility. Starting FUM is +18% on avg FY23; current FUM ~30% above. GQG still has meaningful growth based on the current fund offerings; with the longer-term requiring effective management of the eventual CIO transition and adding new growth avenues to the business. We view the recent re-rate as warranted and valuation still attractive (~11.5x FY24 PE). Add maintained.

CU6 has released initial findings from its Phase 1/2 diagnostic trial in detection prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). The results showed the treatment was broadly safe with only one treatment-related adverse event which resolved, and detected significantly more potential lesions than standard of care imaging. The results have given CU6 confidence to push for a Phase 3 trial, although likely requiring a change in design needed to more accurately validate the volume of positive lesions detected over standard of care.